Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-04-09, Stock:PFE, The news for the past five days is as follows:
2019-04-02: NEWS1: Noteworthy ETF Inflows: VYM, PFE, IBM, AMGN.NEWS2: Noteworthy ETF Inflows: VYM, PFE, IBM, AMGN.NEWS3: Gene-Focused Biotechs Pop After Pfizer Partner Scores In Hemophilia A.NEWS4: Why Sangamo Therapeutics Stock Is Soaring Today.NEWS5: Why Sangamo Therapeutics Stock Is Soaring Today.NEWS6: Sangamo Soars Amid Multiple Development Pipeline Updates.NEWS7: Dow Movers: DWDP, AAPL.NEWS8: Dow Movers: DWDP, AAPL.NEWS9: 3 Healthcare Stocks to Trade Now.NEWS10: See what the IHS Markit Score report has to say about Pfizer Inc..NEWS11: Why Sangamo Therapeutics Stock Is Soaring Today.NEWS12: Gene-Editing Biotechs Pop After Pfizer Partner Scores In Hemophilia A.NEWS13: Trump delays health care vote until after 2020 election.NEWS14: Sangamo Stock Soars on Positive Hemophilia Treatment Trial.NEWS15: Health Care Sector Update for 04/02/2019: ADMA, EVOK, ANGO, JNJ, PFE, ABT, MRK, AMGN.NEWS16: Health Care Sector Update for 04/02/2019: ADMA, EVOK, ANGO, JNJ, PFE, ABT, MRK, AMGN.NEWS17: Sangamo's stock soars after upbeat trial data for hemophilia treatment.NEWS18: Sangamo&apos;s stock soars after upbeat trial data for hemophilia treatment.NEWS19: Sangamo's stock jumps after upbeat trial data for hemophilia treatment.NEWS20: Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy.NEWS21: Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy.
2019-04-03: NEWS1: Top Research Reports for Pfizer, Royal Dutch Shell & Celgene.NEWS2: Top Research Reports for Pfizer, Royal Dutch Shell & Celgene.NEWS3: Top Research Reports for Pfizer, Royal Dutch Shell & Celgene.NEWS4: Sangamo Rises on Positive Phase I/II Hemophilia Study Data.NEWS5: Why the Earnings Surprise Streak Could Continue for Pfizer (PFE).NEWS6: Does Sangamo Have the Best Gene Therapy Program Now?.NEWS7: Does Sangamo Have the Best Gene Therapy Program Now?.NEWS8: Health Care Sector Update for 04/03/2019: EVGN, ADXS, ACHN, JNJ, PFE, ABT, MRK, AMGN.NEWS9: Health Care Sector Update for 04/03/2019: EVGN, ADXS, ACHN, JNJ, PFE, ABT, MRK, AMGN.NEWS10: VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer.NEWS11: Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for April 04, 2019.NEWS12: Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for April 04, 2019.NEWS13: 3 Big Stock Charts for Wednesday: Twitter, Western Union and Wynn Resorts.NEWS14: Micron Technology, Tencent and two dozen other companies most likely to benefit from a China trade deal.
2019-04-04: NEWS1: Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know.NEWS2: U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer.NEWS3: Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval.NEWS4: Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval.NEWS5: The Zacks Analyst Blog Highlights: Pfizer, Royal Dutch, Celgene, Advanced Micro and Blackstone.NEWS6: U.S., China key to GSK's consumer venture with Pfizer.NEWS7: U.S., China key to GSK's consumer venture with Pfizer.NEWS8: Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval.NEWS9: AM Best Affirms Credit Ratings of Blue Whale Re Ltd..NEWS10: The Zacks Analyst Blog Highlights: Pfizer, Royal Dutch, Celgene, Advanced Micro and Blackstone.NEWS11: Health Care Sector Update for 04/04/2019: NSPR, REPH, RWLK, JNJ, PFE, ABT, MRK, AMGN.NEWS12: Health Care Sector Update for 04/04/2019: NSPR, REPH, RWLK, JNJ, PFE, ABT, MRK, AMGN.
2019-04-05: NEWS1: Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU.NEWS2: Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval.NEWS3: Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU.NEWS4: Health Care Sector Update for 04/05/2019: SYRS, AQB, MACK, JNJ, PFE, ABT, MRK, AMGN.NEWS5: Health Care Sector Update for 04/05/2019: SYRS, AQB, MACK, JNJ, PFE, ABT, MRK, AMGN.NEWS6: Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval.NEWS7: Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know.
2019-04-08: NEWS1: After Hours Most Active for Apr 8, 2019 :  AMH, FOLD, AABA, PFE, BILI, QQQ, URBN, BAC, EMB, MRK, SCHW, NEM.NEWS2: After Hours Most Active for Apr 8, 2019 :  AMH, FOLD, AABA, PFE, BILI, QQQ, URBN, BAC, EMB, MRK, SCHW, NEM.NEWS3: Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym.NEWS4: Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym.NEWS5: The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca.NEWS6: Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym.NEWS7: The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca.NEWS8: Health Care Sector Update for 04/08/2019: MDGL, CTST, QURE, JPM, PFE, ABT, MRK, AMGN.NEWS9: Health Care Sector Update for 04/08/2019: MDGL, CTST, QURE, JPM, PFE, ABT, MRK, AMGN.

Answer: Decrease